Abstracts tagged "Biologic drugs"

Abstract Number: 2746 • 2015 ACR/ARHP Annual Meeting
Comparison Study of Tests Available to Monitor Tocilizumab Therapy in Rheumatic Patients
Sergio Martín^1,2, Ainhoa Ruiz del Agua², Nerea Torres², Dora Pascual-Salcedo³, Chamaida Plasencia⁴, Teresa Jurado⁵, Alejandro Balsa⁶, Begoña Ruiz-Argüello², Antonio Martínez², Rosaura Navarro⁷ and Daniel Nagore², ¹Department of Physiology, Medicine and Dentistry School, University of the Basque Country UPV/EHU (Convocatoria ZabaldUZ, UPV/EHU; Departamento de Educación, Universidades e Investigación del Gobierno Vasco, Ref. IT687-13), Leioa, Spain, ²R&D, Progenika-Grifols, Derio, Spain, ³Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ⁴Rheumatology Unit, La Paz University Hospital-Rheumatology, Madrid, Spain, ⁵Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁶Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ⁷Department of Physiology, Medicine and Dentistry School, University of the Basque Country UPV/EHU, Leioa, Spain
Background/Purpose: The options for treatment of rheumatic diseases is constantly growing. Tocilizumab (TCZ) is an anti-interleukin 6 receptor monoclonal antibody indicated for the treatment of severe…
Abstract Number: 689 • 2015 ACR/ARHP Annual Meeting
Are Individual or Country Level Socio-Economic Determinants Related to Disease Activity and Self-Reported Physical Function in Patients with Spondyloarthritis – Results from Multi-National Cross-Sectional Study Comospa
Polina Putrik¹, Sofia Ramiro², Andras Keszei³, Maxime Dougados⁴, Anna Moltó⁵, Désirée van der Heijde², Robert B.M. Landewé⁶ and Annelies Boonen⁷, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Epidemiology, Maastricht University, Maastricht, Netherlands, ⁴Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁵Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité,, Paris, France, ⁶Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁷Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: In RA, previous studies observed inequalities across countries as well as individual level socio-economic factors, and unequal uptake of biologic DMARDs (bDMARDs) played an…
Abstract Number: 3110 • 2015 ACR/ARHP Annual Meeting
In the Multicenter Randomized Controlled Rotation or Change Trial, a Non-TNF Targeted Therapy Has a Higher Efficacy Than a Second Anti-TNF at 3, 6 and 12 Months
Jacques Gottenberg¹, Olivier Brocq², Aleth Perdriger³, Slim Lassoued⁴, Jean-Marie Berthelot⁵, Daniel Wendling⁶, Liana Euller-Ziegler⁷, Martin Soubrier⁸, Christophe Richez⁹, Bruno Fautrel¹⁰, Arnaud Constantin¹¹, Xavier Mariette¹², Jacques Morel¹³, Mélanie Gilson¹⁴, Gregoire Cormier¹⁵, Jean Hugues Salmon¹⁶, Stephanie Rist Bouillon¹⁷, Frederic Lioté¹⁸, Hubert Marotte¹⁹, Christine Bonnet²⁰, Christian Marcelli²¹, Jeremie Sellam²², Olivier Meyer²³, Elisabeth Solau-Gervais²⁴, Sandrine Guis²⁵, Jean Marc Ziza²⁶, Charles Zarnitsky²⁷, Isabelle Chary-Valckenaere²⁸, O Vittecoq²⁹, Alain Saraux³⁰, Yves-Marie Pers³¹, Martine Gayraud³², Gilles Bolla³³, Pascal Claudepierre³⁴, Marc Ardizzone³⁵, Emmanuelle Dernis Labous³⁶, Maxime A. Breban³⁷, Olivier Fain³⁸, Jean Charles Balblanc³⁹, Ouafaa Aberkane⁴⁰, Marion Vazel⁴⁰, Christelle Back⁴⁰, Elodie Perrodeau⁴¹, Jean Sibilia⁴² and Philippe Ravaud³², ¹Hautepierre, Strasbourg, France, ²Hospital Center Princesse Grâce, Monaco, Monaco, ³Service de Rhumatologie, CHU de Rennes, Rennes, France, ⁴Rheumatology, Cahors, France, ⁵Rheumatology, University Hospital, Nantes, France, ⁶Université de Franche-Comté, Besançon, France, ⁷Rheumatology, Nice, France, ⁸Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁹Rheumatology, Bordeaux, France, ¹⁰Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, ¹¹Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ¹²Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ¹³Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ¹⁴Hospital Center, Grenoble, France, ¹⁵Rheumatology, La Roche Sur Yon, France, ¹⁶Hôpital Maison Blanche, Rheumatology, REIMS, France, ¹⁷Rhumatologie, Hopital La Source, La Source, France, ¹⁸Rheumatology, Lariboisière, France, ¹⁹INSERM 1059 / LBTO, Université de Lyon, Saint-Etienne; Rheumatology Department, Saint-Etienne, France, ²⁰Rheumatology, CHU Dupuytren, Limoges, France, ²¹Rheumatology, Caen, France, ²²Rheumatology, PARIS, France, ²³Rheumatology, Hopital Bichat, Paris, France, ²⁴Rhumatologie, University Hospital, Poitiers, France, ²⁵Rheumatology, Marseille, France, ²⁶Hopital Croix-Saint-Simon, Paris Cedex 20, France, ²⁷Rheumatology, Le Havre, France, ²⁸Rheumatology, Nancy, France, ²⁹University Hospital, Rouen, France, ³⁰Rheumatology, Brest, France, ³¹Rheumatology, Montpellier, France, ³²Rheumatology, Paris, France, ³³Rheumatology, Cannes, France, ³⁴Rheumatology, Université Paris Est Créteil, Créteil, France, ³⁵Rheumatology, Centre Hospitalier de Mulhouse, Mulhouse, France, ³⁶Réseau Hôpital et Ville en Rhumatologie (RHEVER) Network, Paris, France, ³⁷Rheumatology, A. Paré University Hospital, Boulogne-Billancourt, France, ³⁸Internal Medicine Department, Saint Antoine Hospital, Paris, France, ³⁹Rheumatology, Belffort, France, ⁴⁰Rheumatology, Strasbourg, France, ⁴¹Epidemiologist, Paris, France, ⁴²Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: As many as one third of patients show insufficient response to their first TNF inhibitor (TNF-insufficient response, TNF-IR). The lack of efficacy of one…
Abstract Number: 977 • 2015 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Active- and Placebo-Controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naïve to Biologic Disease Modifying Anti-Rheumatic Drugs with Active Psoriatic Arthritis
Philip J. Mease¹, Désirée van der Heijde², Christopher T. Ritchlin³, Raquel Cuchacovich^4,5, Catherine L. Shuler⁵, Chin H. Lee⁵, Suvajit Samanta⁵, Chen-Yen Lin⁵, Dafna D. Gladman⁶ and Harald Vangerow⁵, ¹Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ³Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁴School of Medicine, Rheumatology Division, Indiana University, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis which includes peripheral arthritis, enthesitis, dactylitis, and spondylitis manifestations. Ixekizumab, under investigation…
Abstract Number: 3115 • 2015 ACR/ARHP Annual Meeting
Autoantibodies of the IgA Type a Link Between the Gut and the Anti-TNF Therapy Response in Rheumatoid Arthritis Patients Analysed in Two Clinical Trials
Zoltan Konthur¹, Ute Nonhof², Melvin Michael Wiemkes³, Jacqueline Detert³, Tanja Braun⁴, Jörg Hollidt², Gerd Burmester⁵ and Karl Skriner⁵, ¹Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany, ²Drug Response DX GmbH, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: So far no mechanism for non response to biologicals targeting TNFα has been described despite one third of rheumatoid arthritis patients treated are non-responders.…
Abstract Number: 1513 • 2015 ACR/ARHP Annual Meeting
Reactivation of Hepatitis B-Infection in German Patients with Inflammatory Rheumatic Diseases Treated with Biologics – a Monocentric Analysis Involving 1107 Patients
Eva Christina Scharbatke¹, Sonja Kreissl-Kemmer², Hans-Peter Tony³, Marc Schmalzing⁴ and Andreas Geier², ¹Rheumatology/Immunology, University hospital Wuerzburg, Wuerzburg, Germany, ²Hepatology, University hospital Wuerzburg, Wuerzburg, Germany, ³University Hospital Würzburg, Würzburg, Germany, ⁴Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany
Background/Purpose: Hepatitis B virus (HBV) reactivation is a common complication of immunosuppressive treatment in countries with a high prevalence of HBV infection. Biologics – and…
Abstract Number: 1520 • 2015 ACR/ARHP Annual Meeting
Safety, Clinical and Immunologic Effectiveness of the Live Zoster Vaccine Administered to Patients Receiving Anti-TNF Biologics
Jeffrey R. Curtis^1,2, Anita Turner³, Corretta Thomas⁴, Stacey Cofield⁴, Randall Parks⁵, Jennifer H. Ku⁶, Ilhem Messaoudi- Powers⁷, Keith Wanzeck¹ and Kevin L. Winthrop⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama-Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴School of Public Health, University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Casey Eye Institute, Oregon Health & Science Univ, Portland, OR, ⁷Oregon Health and Sciences University, Portland, OR, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: The live herpes zoster vaccine (ZV) has been shown to be safe and effective in large randomized controlled trials of older adults. It is…
Abstract Number: 1531 • 2015 ACR/ARHP Annual Meeting
The Changing Face of Septic Arthritis Complicating Rheumatoid Arthritis in the Era of Biotherapies. Retrospective Single-Center Study over 35 Years
Jean-Jacques Dubost¹, Bruno Pereira², Anne Tournadre³, Zuzana Tatar¹, Marion Couderc¹ and Martin Soubrier¹, ¹Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Biostatistics unit (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France, ³Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France
Background/Purpose: Rheumatoid arthritis (RA) is a risk factor for septic arthritis (SA), and anti-TNF therapy doubles the risk of SA. The purpose of this study…
Abstract Number: 1567 • 2015 ACR/ARHP Annual Meeting
Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting
Matthew Wong-Pack¹, Rod Rodjanapiches¹, Arthur Lau^1,2,3, George Ioannidis^1,3, Sally Wade⁴, Leslie Spangler⁴, Celia JF Lin⁴, Patrick Roy-Gayos¹, William G Bensen^1,3, Robert Bensen³ and Jonathan D Adachi^1,3, ¹McMaster University, Hamilton, ON, Canada, ²Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴Amgen Inc., Thousand Oaks, CA
Background/Purpose: Previous studies combining immunosuppressive biologics have shown an increased risk of infections. Few studies have examined the risk of infection with concurrent use of…
Abstract Number: 430 • 2015 ACR/ARHP Annual Meeting
Adoption of Treat to Target Management in the Context of Achievable Goals and Satisfaction in RA
Peter C. Taylor¹, Juan J Gomez-Reino², Rieke Alten³, Philippe Bertin⁴, Roberto Caporali⁵, Emma Sullivan⁶, Robert Wood⁷, James Piercy⁷, Radu Vasilescu⁸, Dean Spurden⁹ and Jose Alvir¹⁰, ¹Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, ²Desarmen of Rheumatology, Unit Hospital Clinico Universitario, Santiago, Spain, ³Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁴Rheumatology, CHU Dupuytren, Limoges, France, ⁵University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁶Adelphi Real World, Manchester, United Kingdom, ⁷Adelphi Real World, Macclesfield, United Kingdom, ⁸Medical Affairs, Pfizer Inc, Brussels, Belgium, ⁹Pfizer Inc, Tadworth, United Kingdom, ¹⁰Global Health and Value, Pfizer Inc, New York, NY
Background/Purpose: The approach of setting disease activity targets and adjusting therapy appropriately to achieve the target has been proven to optimize outcomes in Rheumatoid Arthritis…
Abstract Number: 1980 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study in France
Alexis Regent¹, Serge Redeker², Alban Deroux³, Pierre Kieffer⁴, Kim Heang Ly⁵, Maxime Dougados⁶, Claire Larroche⁷, Loïc Guillevin¹, Laurence Bouillet⁸, Olivier Espitia⁹, Nathalie Costedoat-Chalumeau¹⁰, Martin Soubrier¹¹, Benoit Brihaye¹², François Lifermann¹³, Guillaume Lefèvre¹⁴, Xavier Puéchal¹, Luc Mouthon¹, Eric Toussirot¹⁵ and GFEV and CRI, ¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ²43 rue de l'isle, Ch Abbeville, Abbeville, France, ³Internal Medicine, CHU Grenoble, Grenoble, France, ⁴Hopital Emile Muller, Mulhouse Cedex 1, France, ⁵CHU de Limoges, Service de médecine interne, Limoges, France, ⁶Medicine Faculty, Paris-Descartes University, Paris, UPRES-EA 4058, Cochin Hospital, Rheumatology B, Paris, France, ⁷Internal Medicine, Paris, France, ⁸CHU, Grenoble, France, ⁹Internal Medicine, Nantes University Hospital, Nantes, France, ¹⁰Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ¹¹Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ¹²Service de médecine interne et médecine polyvalente, Saint Quentin, France, ¹³CH Dax, Dax, France, ¹⁴Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, ¹⁵Service de Rhumatologie, CHU J Minjoz, Besancon, France
Background/Purpose: To report the French experience on the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA) and outcome after treatment…
Abstract Number: 432 • 2015 ACR/ARHP Annual Meeting
Additional Intensive Treatment for Rheumatoid Arthritis Patients with Positive Power Doppler Signals Reduce the Radiological Joint Damage Even after Achieving Clinical Remission -SCRUM Study-
Tadashi Okano¹, Kentaro Inui², Masahiro Tada³, Yuko Sugioka⁴, Kenji Mamoto¹, Tatsuya Koike⁴ and Hiroaki Nakamura¹, ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orthopedic surgery, Osaka City General Hospital, Osaka, Japan, ⁴Center for Senile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: The latest recommendations for the treatment of rheumatoid arthritis (RA) focus on the achievement of clinical remission. However, joints with subclinical positive power Doppler…
Abstract Number: 2059 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Inhibitor Tapering Induced Radiographic Progression Is Driven By Weighted Mean Disease Activity over Time, Not Flaring or Lower TNFi Exposition
Alfons A. den Broeder¹, Chantal A.M. Bouman¹, Aatke van der Maas², Frank H.J. van den Hoogen¹, Noortje van Herwaarden¹ and R. Landewe³, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Hengstdal 3, Sint Maartenskliniek, Nijmegen, Netherlands, ³Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, Maastricht, Netherlands
Background/Purpose: DRESS, a randomized controlled strategy trial (RCT)1investigating disease activity guided tapering of etanercept and adalimumab compared to usual care in RA patients, indicated that…
Abstract Number: 446 • 2015 ACR/ARHP Annual Meeting
Low Disease Activity at 12 Weeks and 24 Weeks Is Predictive of Normalized Health-Related Quality of Life in Methotrexate-Experienced Patients with Active Rheumatoid Arthritis Treated with Intravenous Golimumab Plus Methotrexate
Clifton O. Bingham III¹, Michael Weinblatt², Rene Westhovens³, Lilianne Kim⁴, Chenglong Han⁵, Stephen Xu⁴, Kim Hung Lo⁴, Kezhen L. Tang⁴, Elizabeth C. Hsia^4,6, Dennis Parenti⁷ and Shelly Kafka⁷, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Brigham and Women's Hospital, Boston, MA, ³UZ Gasthuisberg, Leuven, Belgium, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Global Services, LLC, Malvern, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: Previous analyses in patients (pts) with rheumatoid arthritis (RA) have evaluated the relationship between controlling disease activity and achieving long-term improvements in health-related quality…
Abstract Number: 2145 • 2015 ACR/ARHP Annual Meeting
Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Alice B. Gottlieb¹, Philip J. Mease², Raquel S. Cuchacovich^3,4, Catherine L. Shuler⁵, Chen-Yen Lin⁵, Russel T. Burge⁵, Suvajit Samanta⁵, Chin H. Lee⁵ and Dafna D. Gladman⁶, ¹Dermatology, Tufts Medical Center, Boston, MA, ²Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ³School of Medicine, Rheumatology Division, Indiana University, Indianapolis, IN, ⁴Bio Medicines Business Unit/Autoimmune Medical, Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis, peripheral arthritis, enthesitis, dactylitis, and spondylitis. PsA has a significant negative impact…

« Previous Page
1
…
7
8
9
10
11
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].